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A b s t r a c t
Obesity is directly and strongly associated with hypertension and left ventricular hypertrophy (LVH). Development of
LVH is multifactorial, caused both by haemodynamic and non-haemodynamic factors. Hypertension is the main haemo-
dynamic factor. Humoral mechanisms, as a non-haemodynamic factor for LVH development, have not been completely
explained. The aim of this study is to determine whether hyperleptinemia can be one of humoral – non-haemodynamic
factor inducing LVH together with haemodynamic factors in overweight females. The study was done on thirty six adult,
overweight female patients, body mass index in range 25–30 kg/m2. Patients are nondiabetic with regular renal function.
Twenty one female patients were hypertensive with left ventricular hypertrophy. Control group included fifteen hyperten-
sive female patients without left ventricular hypertrophy. In all patients was determined glucose profile and creatinine
clearance, cholesterol, triglycerides, LDL, HDL. Weight, high, circumference of the waist and hips was taken. Cardiovas-
cular determination was done applying two-dimensional ultrasound. Serum leptin level was measured using radio-
immunoassay method (RIA). Results showed that serum leptin level was significantly higher in hypertensive, overweight
females with LVH. This suggests that non-haemodynamic factors, such as hyperleptinemia, participate in left ventricu-
lar hypertrophy development together with haemodynamic factors in adult hypertonic, overweight females.
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Introduction
Obesity is strongly related to arterial hypertension.
Both are part of metabolic syndrome X¹. Uncorrected
obesity often leads to atherosclerosis, increased blood
pressure, cardiac hypertrophy and other vascular compli-
cations2. Left ventricular hypertrophy (LVH) is a strong
predictor of cardiovascular events. Patients with LVH
are at increased risk for sudden cardiac death, coronary
heart disease and congestive heart failure3. Development
of LVH is multifactorial, caused by haemodynamic and
non-haemodynamic factors4, including preload, afterload
and neurohumoral mechanisms. Hypertension is the
main haemodynamic risk factor for the development of
LVH. Non-haemodynamic factors, such as local and sys-
temic neurohumoral changes, contribute to development
of LVH5 and they have not been completely explained.
Hyperleptinemia could be one of the neurohumoral me-
chanisms inducing left ventricular hypertrophy together
with haemodynamic factors.
Leptin is a product of ob-gene, produced mostly in
adipocytes and less in the skeletal muscles, heart, vessels
and brain, so that it also has local autocrine/paracrine ef-
fects in addition to its systemic action, mediated by circu-
lating leptin6. Physiologically leptin has circadian varia-
tions in its secretion witch is lost in condition of fatness7.
Serum leptin concentration is proportional to body mass
and it is significantly increased in obesity8. Obesitiy is
characterised by hyperleptinemia and possible selective
metabolic leptin resistence, while sympathoexcitatory
action of leptin is preserved9. Through stimulation of
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cardiac sympathetic system leptin increases heart rate
and blood pressure, and thus imposes greater workload
on the heart causing pathophysiological changes of the
heart2. Leptin also possesses cardio-renal actions which
contribute to obesity-related hypertension10 and lead to
left ventricular hypertrophy.
The potential actions of leptin in pathophysiology of
cardiovascular complications are still analysed. Most in-
formation about cardiovascular actions of leptin has
been obtained in in-vitro and animal studies, so that fur-
ther research in humans is widely awaited10. Leptin re-
ceptors have been isolated in rat cardiomyocytes but di-
rect effects of leptin on cardiac structure and function
still remains to be determined11. It has not been ex-
plained yet whether leptin affects left ventricular wall
thickness in overweight adult humans.
Materials and Methods
Patients
The research was carried out on 36 adult female pa-
tients with personal history of essential hypertension for
at least five years and according to their medical docu-
mentation (Table 1). Arterial hypertension is defined as
blood pressure above 140/90 mm Hg. Presence of second-
ary hypertension is excluded in all patients. They were
divided into two groups according to existence of LVH: 21
patients with left ventricular hypertrophy and 15 pa-
tients without LVH. In all patients body mass index
(BMI) was in range 25–30 kg/m2. Exclusion criteria for
the study were glucose intolerance, diabetes mellitus, in-
creased creatinine level in the morning serum taken on
an empty stomach, valvular heart disease, left ventricu-
lar ejection fraction below 50% and stroke. All women
were postmenopausal and possible effect of estrogen is
excluded.
All patients were hospitalized on Department for Car-
diovascular medicine because of first myocardial infarc-
tion and arterial hypertension. According to recent stud-
ies, serum leptin level is increased after myocardial
infarction, but it returns to normal values six days fol-
lowing the incident12. This means that when the samples
were taken to determine leptin level there was no influ-
ence of coronary incident on serum leptin level. There
were neither early nor late acute complications after
myocardial infarction, such as arrhythmias, pericarditis,
heart failure, cardiogenic shock.
They were treated with nitrates, beta blockers and
ACE inhibitors. According to recent studies, ACE inhibi-
tors reduce proinflammatory and thrombogenic cyto-
kines, such as leptin13.
In hospital environment they all had normal blood
pressure level. Systolic blood pressure was less than 140
mm Hg and diastolic blood pressure was less than 90 mm
Hg, taken three times a day during hospitalization. They
were discharged from hospital fourteen days after acute
event in stable condition.
Patient’s history, clinical examination, electrocardiog-
raphy, X-ray of the thorax, biochemical blood analysis,
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TABLE 1
DEMOGRAPHIC, ANTHROPOMETRIC, BIOCHEMICAL AND ECHOCARDIOGRAPHIC DATA
Hypertensive females with LVH Hypertensive females without LVH
N(%) 21 (52) 15 (50)
Age (years) 69 ±7 60 ± 8
Weight (kg) 72.28 ± 8.95 68.73 ± 5.68
BMI (kg/m²) 27.61 ± 2.05 26.50 ± 1.80
Wc (cm) 95.619 ± 6.368 89.267 ± 8.811
Hc (cm) 101.952 ± 6.652 97.933 ± 6.766
Bg (mmol/L) 5.543 ± 0.751 5.753 ± 0.485
Serum creatinine (mmol/L) 72.857 ± 12.854 74.867 ± 10.616
Cc (mL/min) 89.178 ± 24.093 92.245 ± 22.627
Cholesterol (mmol/L) 5.920 ± 1.426 5.387 ± 1.503
Tryglicerides (mmol/L) 1.751 ± 0.773 1.823 ± 0.814
LDL (mmol/L) 3.498 ± 1.117 3.071 ± 1.403
HDL /mmol/L) 1.271 ± 0.593 1.209 ± 0.339
Leptin level (ng/mL) 26.992 ± 15.899 16.707 ± 6.911
IVS (mm) 14.667 ± 2.033 10.267 ± 0.799
PWT (mm) 12.810 ± 0.680 9.067 ± 0.799
EF (%) 59.762 ± 7.993 60.8 ± 6.516
Mean ± SD, unless otherwise stated
LVH – left ventricle hypertrophy, BMI – body mass index, Wc – waist circumference, Hc – hips circumference, Bg – blood glucose,
Cc – creatinine clearance, IVS – intraventricular septum, PWT – posterior wall thickness, EF – ejection fraction
leptin level and two-dimensional echocardiography were
taken for each patient. All patients gave their written in-
formed consent. The study was approved by ethical com-
mittees of our institutions.
Anthropometric determinations
The most common methods for diagnosing over-
weight and obesity are based on BMI (kg/m²)14. Weight
and height were measured by standard techniques. Body
mass index was calculated as body weight divided by
height squared. Waist end hips circumference was taken
by tape measure. Waist circumference was measured at
the umbilical level, in the middle between the lowest rib
and the iliac crest. Hip circumference was measured at
the trochanter level15.
Biochemical blood analysis
Blood glucose level, serum creatinine level and lipido-
gram were measured in all patients. Blood samples for
biochemical analysis were taken in the morning, on an
empty stomach. All patients had regular blood glucose
values, measured five times during hospitalization and
according to glucose profiles. Also, they all had regular
creatinine serum level. Cholesterol, triglyceride, LDL,
HDL were measured before hypolipemic therapy. Crea-
tinine clearance was calculated using Cockcroft-Gault
equation.
Cardiovascular determinations
In all patients a 12-lead ECG was performed two
times a day to monitor coronary heart disease stabiliza-
tion. Also, X-ray of the thorax was taken to evaluate the
left ventricular enlargement.
Echocardiographic determinations were obtained by
two-dimensional ultrasound Siemens Acuson CV 70 with
cardiologic probe P4-2. During the examinations pa-
tients were lying in the left lateral position. Intraventri-
cular septum (IVS) and posterior wall thickness (PWT)
of the left ventricle as well as ejection fraction were de-
termined by M-mode technique16. Echocardiographic me-
asurements were taken according to Textbook of Clinical
Echocardiography by Otto (3rd edition, Elsevier Soun-
ders 2004), where the referent value defining LVH in
both sexes was 12 mm or more. The data were classified
into two groups, regarding IVS and PWT. Both patients
with LVH and patients without LVH were examined.
Ejection fraction was measured according to Teichholz,
and all the patients had normal value, which is 50% or
higher.
Leptin determination
Blood samples for leptin were taken from all subjects
between 7 and 7:30 a.m. on the twelfth day after myocar-
dial infarction, on an empty stomach. Serum leptin level
was measured using radioimmunoassay method12, RIA-
-CT KIPMR44, Biosource Europe S.A, Nivelles, Belgium.
It is a radioimmunoassay with Coated Tubes for quanti-
tative detection of human leptin in serum and plasma
(coefficient of variation 7.3 ± 1.1%).
Statistical methods
Data are presented as mean ± SD. All statistical tests
were two-sided and carried out to a significance level (P)
of 0.05. Shapiro-Wilks test of normality was used to test
leptin distribution in hypertensive patients with left ven-
tricular hypertrophy. According to results of Shapiro-
-Wilks test we used nonparametric Mann-Whitney test.
Spearman method was used to assess univariate rela-
tions. The value P<0.05 was considered statistically sig-
nificant. Data were prepared for analysis in Microsoft
Excel 2003. Statistical analysis was made by SPSS 15.0
for Windows Evaluation Version and Statistica 7.1.
Results
Clinical characteristics for both groups are given in
Table 1. All the patients were adults without significant
differences in their build. They all had normal blood glu-
cose and serum creatinine in the morning. There were no
significant statistical differences in values of cholesterol,
triglycerides, LDL and HDL between the groups.
All patients were hypertensive adult females and they
were divided into two groups regarding the presence of
LVH. LVH is characterised by intraventricular wall thi-
ckness, as the most significant indicator of LVH, and by
posterior wall thickness. Ejection fraction (EF) was pre-
served in all patients, above 50%.
76.2% of female patients with LVH had increased serum
leptin level in relation to referent leptin values for non
obese adult females with BMI 18–25 kg/m2 (6.15–10.5 ng/
mL, according to Biosource Europe S.A., Nivelles, Belgium).
Leptin levels were statistically significantly higher in
hypertensive females with left ventricular hypertrophy
than in female group without LVH (p=0.025) (Figure 1).
Serum leptin level did not have positive correlation
with intraventricular wall thickness in females with LVH
(p=0.850) and with posterior wall thickness of the LV
(p=0.332).
Anthropometric measurements were taken in all pa-
tients. Correlation analysis was made between leptin
level and waist and hips circumference in female patients
with LVH. Leptin level correlated positively with waist
circumference in hypertensive females with LVH (R²=
0.281, p=0.025). There was no positive correlation be-
tween leptin level and hips circumference in female pa-
tients with LVH (p=0.063).
Also, Spearmann method was used to analyze correla-
tion between lipidogram and leptin level in both groups
of patients, with and without LVH. There was positive
correlation between cholesterol level and leptin level in
female patients with LVH (R²=0.203, p=0.049). Triglyc-
erides, LDL and HDL did not show positive correlation
with leptin level in any group of patients.
Discussion and Conclusion
This study presents influence of one of the neuro-
humoral mechanisms on myocardial growth together
with haemodynamic factors in adult overweight females.
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The results showed that plasma leptin concentration
(1) was higher in hypertensive female patients with LVH
than in female patients without LVH, (2) positively cor-
related with waist circumference in females with LVH,
(3) positively correlated with cholesterol level in female
patients with LVH and (4) did not have positive correla-
tion with intraventricular and posterior wall thickness in
females with LVH.
This study provides data on relation between serum
leptin concentrations and left ventricular hypertrophy in
hypertensive moderately obese adult females.
Up-to-date scientific information on leptin physiology
showed that leptin levels increase exponentially with fat
mass increase, and most obese humans have increased
leptin level17. It was believed that leptin is produced only
by adipose tissue, but recent studies have shown that
leptin expression has been identified in many other tis-
sues, even in the heart6. Rat cardiomyocytes express all
components of leptin system and show sex differences.
Synthesis of leptin and leptin receptors was significantly
higher in the heart of female rats18. Moreover, research
in humans showed that sex influences plasma leptin
level. Women have significantly higher leptin concentra-
tions than men regardless of their fat mass19. Tachycar-
dia and increased systolic and diastolic blood pressure
are associated with high serum leptin level in adult obese
females20. In obese humans, hyperleptinemia increases
the risk for cardiovascular complications. Simultaneou-
sly, there is possible selective leptin metabolic resistence
and preserved cardiovascular sympatho-excitatory ac-
tions of leptin, resulting in higher arterial pressure21 and
heart rate increase2. It is also confirmed that only cen-
trally administred leptin and chronic leptin infusion in-
crease blood pressure22. Consequently, it cannot be ruled
out that high blood pressure caused by hyperleptinemia
contributes to leptin induced myocardial changes, such
as hypertrophy23.
Hypertension has strong influence on the left ventri-
cle mass and some neurohumoral systems are considered
to have direct influence on left ventricular wall thick-
ness24. Some studies discussed leptin as a possible neuro-
humoral factor in development of leptin-related LVH22,
but there is still question whether it has direct or indi-
rect effect. In experimental conditions, some studies sho-
wed that leptin does not induce cardiomyocytes hyper-
trophy25, but the latest studies showed that leptin exerts
direct hypertrophic effect on cultured cardiomyocytes in
condition after coronary artery ligation26. Considering all
that, there is need for further research on correlation be-
tween leptin and cardiovascular disease in humans27.
This study showed that hyperleptinemia together with
haemodynamic factors contributes to development of
LVH in adult overweight females. It confirmed that lep-
tin did not correlate independently and directly with
intraventricular wall thickness and posterior wall thick-
ness of the left ventricle.
Production of leptin receptors and leptin in the hu-
mans cardiomyocytes6 suggest that overweight women
with LVH, besides adipocytes leptin production, had
higher leptin system synthesis in the myocardium. Ac-
cording to results from this study main consequences on
myocard result from central leptin action and less from
local autocrine/paracrine action. In such conditions,
pathophysiology of leptin-related LVH can be explained
by haemodynamic and non-haemodynamic factors. Cen-
tral effect of leptin is increase of blood pressure and
heart frequency. In that way volume and pressure over-
load, as haemodynamic factors, become main factors in































Fig. 2. Hypothetic algorithm of haemodynamic and non-haemo-
dynamic pathway in development of LVH in hypertensive adult





















Fig. 1. Differences between leptin level in hypertensive females
with LVH and hypertensive females without LVH.
development of leptin-related LVH. Simultaneous to cen-
tral action, there is local leptin action, which affects
cardiomyocytes, and it should not be neglected. This ef-
fect is mediated by specific leptin receptors and involves
complex and multifaceted cell-signaling pathway28. It
can be concluded that leptin in the myocard presents
neurohumoral, non haemodynamic pathway in develop-
ment of LVH in hypertensive overweight adult females
(Figure 2).
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HIPERLEPTINEMIJA – NEHEMODINAMSKI RIZI^NI FAKTOR ZA RAZVOJ HIPERTROFIJE
LIJEVE KLIJETKE KOD HIPERTONI^NIH PRETILIH @ENA
S A @ E T A K
Pretilost je direktno i sna`no povezana s hipertenzijom i hipertrofijom lijeve klijetke (HLV). Razvoj HLV je multi-
faktorijalna, uzrokovana hemodinamskim i nehemodinamskim faktorima. Hipertenzija je glavni hemodinamski faktor.
Humoralni mehanizmi – nehemodinamski faktori za razvoj HLV, nisu jo{ u potpunosti razja{njeni. Cilj studije je odre-
diti mo`e li hiperleptinemija biti jedan od humoralnih – nehemodinamskih faktora koja inducira razvoj HLV zajedno s
hemodinamskim faktorima kod `ena s prekomjernom tjelesnom te`inom. Studija je provedena na 36 odraslih `ena, s
prekomjernom tjelesnom te`inom, BMI 25–30 kg/m². Pacijentice su uredne bubre`ne funkcije, bez {e}erne bolesti. Ispi-
tivanu skupinu ~ini 21 pacijentica s arterijskom hipertenzijom i razvijenom HLV, a kontrolnu skupinu ~ini 15 pacijen-
tica s arterijskom hipertenzijom a bez razvijene HLV. Svim ispitanicama odre|en je profil glukoze, klirens kreatinina,
kolesterol, trigliceridi, LDL, HDL. Mjerena je te`ina, visina, opseg struka i bokova. Kardiovaskularne mjere dobivene
su dvodimenzionalnim ultrazvukom. Razina leptina u serumu odre|ena je radioimmunoassay metodom (RIA). Rezul-
tati su pokazali da je razina serumskog leptina zna~ajno ve}a kod hipertoni~nih `ena s prekomjernom tjelesnom te`i-
nom koje imaju razvijenu HLV. Mo`emo zaklju~iti da nehemodinamski faktori, kao hiperleptinemija, sudjeluju u raz-
voju hipertrofije lijeve klijetke zajedno s hemodinamskim faktorima kod odraslih, hipertoni~nih `ena s prekomjernom
tjelesnom te`inom.
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